This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chen, J. J. Articles by Pahwa, R. Search for Related Content Social Bookmarking                   What's this?

Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease

Schools of Medicine and Pharmacy, Movement Disorders Center, Loma Linda University, Loma Linda, California, jjchen{at}llu.edu

Rajesh Pahwa, MD

Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas

The most efficacious symptomatic agent for Parkinson's disease is levodopa; however, the development of motor complications with long-term therapy is concerning. In the modern day treatment of Parkinson's disease, non-levodopa agents (eg, dopamine agonists, monoamine oxidase type B inhibitors) should be considered as appropriate initial treatments. In early Parkinson's disease, dopamine agonists provide effective symptomatic therapy, reduce the risk for motor complications, and delay the need to initiate levodopa. However, the dopamine agonists are associated with impulse control disorders and behaviors that are concerning. Monoamine oxidase type B inhibitors are also effective as monotherapy for early stage Parkinson's disease. Clinical data demonstrate that early initiation of rasagiline (in the absence of functional impairment) is associated with improved outcomes as opposed to delayed initiation. Selegiline can delay the need for levodopa, albeit its clinical effectiveness as monotherapy is equivocal. When selecting initial therapy for early Parkinson's disease, clinicians must consider both short-term and long-term benefits and risks.

Key Words: Dopamine agonists • levodopa • monoamine oxidase inhibitors • Parkinson's disease • pramipexole • rasagiline • ropinirole • selegiline

Journal of Pharmacy Practice, Vol. 21, No. 4, 244-253 (2008)
DOI: 10.1177/0897190008318129


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?